Skip to Content

Edarbyclor Approval History

  • FDA approved: Yes (First approved December 20th, 2011)
  • Brand name: Edarbyclor
  • Generic name: azilsartan medoxomil and chlorthalidone
  • Dosage form: Tablets
  • Company: Takeda Pharmaceutical Company Limited
  • Treatment for: High Blood Pressure

Edarbyclor (azilsartan medoxomil and chlorthalidone) is a fixed-dose combination of an angiotensin II receptor blocker (ARB) and a diuretic, indicated for the treatment of hypertension.

Development History and FDA Approval Process for Edarbyclor

Dec 20, 2011Approval FDA Approves Edarbyclor (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.